Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Average Recommendation of “Buy” from Brokerages

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) has been assigned a consensus recommendation of “Buy” from the ten analysts that are currently covering the company, Marketbeat.com reports. Eight analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $44.71.

A number of research firms have recently weighed in on DNTH. Baird R W raised shares of Dianthus Therapeutics to a “strong-buy” rating in a research report on Friday, July 26th. Wedbush decreased their price objective on shares of Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating for the company in a research note on Friday, August 9th. Lifesci Capital upgraded Dianthus Therapeutics to a “strong-buy” rating in a research note on Tuesday, June 11th. Cantor Fitzgerald initiated coverage on shares of Dianthus Therapeutics in a research note on Thursday, June 27th. They set an “overweight” rating on the stock. Finally, HC Wainwright reiterated a “buy” rating and issued a $40.00 price target on shares of Dianthus Therapeutics in a research note on Monday, August 12th.

Hedge Funds Weigh In On Dianthus Therapeutics

Several large investors have recently modified their holdings of the stock. SG Americas Securities LLC bought a new stake in Dianthus Therapeutics in the second quarter valued at about $112,000. The Manufacturers Life Insurance Company acquired a new position in shares of Dianthus Therapeutics in the 2nd quarter worth approximately $236,000. WINTON GROUP Ltd acquired a new position in shares of Dianthus Therapeutics in the 2nd quarter worth approximately $265,000. Point72 DIFC Ltd bought a new stake in shares of Dianthus Therapeutics in the 2nd quarter valued at approximately $334,000. Finally, Virtu Financial LLC acquired a new stake in shares of Dianthus Therapeutics during the 1st quarter valued at approximately $390,000. Institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Stock Performance

Shares of DNTH stock opened at $25.99 on Wednesday. Dianthus Therapeutics has a 1 year low of $6.58 and a 1 year high of $33.77. The stock has a fifty day moving average price of $28.12 and a 200 day moving average price of $26.11. The stock has a market cap of $762.81 million, a PE ratio of -4.46 and a beta of 1.85.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by ($0.01). The company had revenue of $1.86 million for the quarter, compared to analyst estimates of $0.63 million. Dianthus Therapeutics had a negative return on equity of 21.03% and a negative net margin of 1,376.42%. As a group, equities research analysts predict that Dianthus Therapeutics will post -2.32 earnings per share for the current year.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.